RZLT Rezolute
- 2.560
- -0.090-3.40%
Rezolute News
HC Wainwright & Co. : Rezolute (RZLT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
HC Wainwright & Co. : Rezolute (RZLT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $14 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $14 price target.
Buy Rating Affirmed for Rezolute Amidst Clinical Progress and Market Opportunity
Rezolute's Promising Pipeline and Financial Stability Bolster Buy Rating
Rezolute (RZLT.US): The 2024 Q3 earnings report achieved revenue of $0, with a previous value of $0; earnings per share of -0.34 dollars, previous value of -0.30 dollars, expected value of -0.31 dollars.
Rezolute (RZLT.US): The 2024 Q3 earnings report achieved revenue of $0, with a previous value of $0; earnings per share of -0.34 dollars, previous value of -0.30 dollars, expected value of -0.31 dollars.
Rezolute | 10-Q: Quarterly report
Rezolute 1Q R&D Expenses $12.4M >RZLT
Rezolute 1Q R&D Expenses $12.4M >RZLT
Rezolute 3Q Loss/Shr 34c >RZLT
Rezolute 3Q Loss/Shr 34c >RZLT
Press Release: Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyp
Rezolute to Present Phase 2 RIZE Study at PES Meeting
Phase 2 RIZE Study Sub-Analyses To Be Presented At 2024 Pediatric Endocrine Society Annual Meeting
Phase 2 RIZE Study Sub-Analyses To Be Presented At 2024 Pediatric Endocrine Society Annual Meeting
J.P. Morgan Securities: Rezolute (RZLT.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $7.00.
J.P. Morgan Securities: Rezolute (RZLT.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $7.00.
JMP Securities Reiterates Market Outperform on Rezolute, Maintains $7 Price Target
JMP Securities analyst Jason Butler reiterates Rezolute (NASDAQ:RZLT) with a Market Outperform and maintains $7 price target.
Rezolute Initiated at Buy by JonesTrading
Rezolute Initiated at Buy by JonesTrading
JonesTrading Initiates Coverage On Rezolute With Buy Rating, Announces Price Target of $10
JonesTrading analyst Catherine Novack initiates coverage on Rezolute with a Buy rating and announces Price Target of $10.
Optimistic Buy Rating for Rezolute's RZ402 Drug Candidate Amid Promising DME Treatment Prospects
Rezolute Initiated at Buy by Maxim Group
Rezolute Initiated at Buy by Maxim Group
Rezolute (RZLT.US) was first covered by Maxim Group and given a buy rating, with a target price of $8.00.
Rezolute (RZLT.US) was first covered by Maxim Group and given a buy rating, with a target price of $8.00.
Maxim Group Initiates Coverage On Rezolute With Buy Rating, Announces Price Target of $8
Maxim Group analyst Jason McCarthy initiates coverage on Rezolute with a Buy rating and announces Price Target of $8.
CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders inte
Analysis
Price Target
No Data
